Tabimorelin
NN703 · NNC 26-0161
Tabimorelin stands as a massively potent, orally active Growth Hormone Secretagogue (GHS) that pushed deep into Phase II clinical trials for severe adult GH deficiency. Operating as a highly engineered, true peptide-mimetic, it successfully breached the gastric barrier without requiring injection. While ultimately shelved by pharma in favor of highly profitable recombinant HGH, it remains a testament to elite secretagogue engineering designed to maximize natural pulsatile release.
Use-case scores
0–10 against the evidence we have, not a gym ranking. Hidden domains do not apply here.
- Muscle / recomp3/10
Historical oral ghrelin-mimetic program. Not MK-677. Not a living obesity NDA.
Compound card
- Class
- Oral GHS-R1a agonist (NN703 class; not ibutamoren)
- Formula
- C32H39N5O4
- Status
- Not FDA-approved · research use
How it works
Tabimorelin (NN703) is a synthetic, orally active non-peptide growth hormone secretagogue (GHS). Like Ibutamoren (MK-677), it was designed to mimic ghrelin and bind to the ghrelin receptor (GHS-R1a) to stimulate a powerful, pulsatile release of naturally occurring human growth hormone (HGH) and IGF-1 from the pituitary gland.
It was developed as a potential oral treatment for age-related growth hormone deficiency (somatopause) and frailty. While it effectively raises IGF-1 levels, it holds lower affinity than MK-677 and development was largely paused in clinical trial phases.
Source: PMID: 11401563
Background & History
Tabimorelin (NN703) was developed by Novo Nordisk as a potential oral alternative to GH injections for growth hormone deficient adults. It entered Phase II clinical trials in the early 2000s showing dose-dependent GH elevation, but the magnitude of IGF-1 increase and clinical endpoints were modest compared to established GH replacement therapy. Development was discontinued, but tabimorelin remains an important reference compound in the growth hormone secretagogue field.
Research Use Cases
- ✓GH deficiency research
- ✓Oral GH secretagogue development
- ✓GHS-R1a pharmacology research
Dosing
| Phase | Dose | Frequency | Notes |
|---|---|---|---|
| Research / Clinical Trials | Oral capsule | Daily | Abandoned in clinical trials. Replaced functionally in research/market by the more potent Ibutamoren (MK-677). |
Administration
Timeline
Who it is for
Growth Hormone Secretagogue
LowHistorical interest; essentially a lesser-known, discontinued analogue conceptually identical to MK-677.
Safety & Considerations
Not FDA approved. Like all ghrelin mimetics, likely induces severe hunger and temporary insulin resistance.
Regulatory & Legal Status
Not currently on the WADA 2026 Prohibited List. Policies may change - verify before competition.
Research Chemical
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Limits of current evidence
- Not interchangeable with MK-677.
Verdict
Tabimorelin is an older oral GH secretagogue. Do not treat it as ibutamoren. Development history is not a 2026 pharmacy SKU.
Interactions & Contraindications
May increase cortisol and prolactin transiently. Similar drug interaction profile to other ghrelin mimetics - caution with insulin-sensitizing agents due to potential GH-mediated insulin resistance.
Synergies & Common Stacks
Both are oral GHS-R1a agonists. MK-677 is a non-peptide while tabimorelin is a peptide-mimetic - useful for comparing structural class effects on GH secretion patterns.
Tabimorelin and GHRP-2 share the GHS-R1a mechanism. Comparing oral (tabimorelin) vs injectable (GHRP-2) routes.
Frequently Asked Questions
Is Tabimorelin a peptide?▼
Looking for a trusted source? See our recommended suppliers
Independently tested · COA-verified · Save 10% with our exclusive code